India markets open in 1 hour 6 minutes
  • BSE SENSEX

    52,474.76
    +174.26 (+0.33%)
     
  • Nifty 50

    15,799.35
    +61.55 (+0.39%)
     
  • Dow

    34,479.60
    +13.40 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.12 (+0.35%)
     
  • BTC-INR

    2,854,153.50
    +245,250.25 (+9.40%)
     
  • CMC Crypto 200

    976.25
    +34.44 (+3.66%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • Nikkei

    29,099.92
    +151.19 (+0.52%)
     
  • EUR/INR

    88.6707
    -0.0373 (-0.04%)
     
  • GBP/INR

    103.3710
    +0.0476 (+0.05%)
     
  • AED/INR

    19.8950
    0.0000 (0.00%)
     
  • INR/JPY

    1.4952
    +0.0008 (+0.05%)
     
  • SGD/INR

    55.2420
    -0.0100 (-0.02%)
     

Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.

A live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events. An archived replay of the webcast will be available on the Company's website following the live presentation.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006